Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

  • Showing results for a modified search because your search retrieved no results.
1.

Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials.

Ailawadhi S, Jacobus S, Sexton R, Stewart AK, Dispenzieri A, Hussein MA, Zonder JA, Crowley J, Hoering A, Barlogie B, Orlowski RZ, Rajkumar SV.

Blood Cancer J. 2018 Jul 6;8(7):67. doi: 10.1038/s41408-018-0102-7.

2.

Daratumumab proves safe and highly effective in AL amyloidosis.

Khouri J, Kin A, Thapa B, Reu FJ, Bumma N, Samaras CJ, Liu HD, Karam MA, Reed J, Mathur S, Faiman BM, Devries G, Zonder J, Valent J.

Br J Haematol. 2018 Jun 25. doi: 10.1111/bjh.15455. [Epub ahead of print] No abstract available.

PMID:
29938774
3.

The difficult business of assessing new therapies for smouldering multiple myeloma.

Zonder JA.

Br J Haematol. 2018 May 16. doi: 10.1111/bjh.15385. [Epub ahead of print] No abstract available.

PMID:
29767407
4.

Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic.

Simonsen L, Higgs E, Taylor RJ, Wentworth D, Cozzi-Lepri A, Pett S, Dwyer DE, Davey R, Lynfield R, Losso M, Morales K, Glesby MJ, Weckx J, Carey D, Lane C, Lundgren J; INSIGHT FLU002 and FLU003 Study Groups .

Clin Infect Dis. 2018 Jul 18;67(3):341-349. doi: 10.1093/cid/ciy088.

PMID:
29746631
5.

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.

Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK.

J Clin Oncol. 2018 Mar 20;36(9):859-866. doi: 10.1200/JCO.2017.75.5207. Epub 2018 Jan 30.

PMID:
29381435
6.

A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.

Spencer A, Harrison S, Zonder J, Badros A, Laubach J, Bergin K, Khot A, Zimmerman T, Chauhan D, Levin N, MacLaren A, Reich SD, Trikha M, Richardson P.

Br J Haematol. 2018 Jan;180(1):41-51. doi: 10.1111/bjh.14987. Epub 2017 Oct 26.

PMID:
29076150
7.

Transplantation for Myeloma - Now or Later?

Schiffer CA, Zonder JA.

N Engl J Med. 2017 Apr 6;376(14):1378-1379. doi: 10.1056/NEJMe1700453. No abstract available.

PMID:
28379801
8.

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.

Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf JL, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W.

Cancer Epidemiol Biomarkers Prev. 2016 Dec;25(12):1609-1618. Epub 2016 Sep 1.

9.

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.

Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Schönland S, Walling J, Kinney GG, Koller M, Schenk DB, Guthrie SD, Liedtke M.

J Clin Oncol. 2016 Apr 1;34(10):1097-103. doi: 10.1200/JCO.2015.63.6530. Epub 2016 Feb 8.

10.

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.

Usmani SZ, Sexton R, Ailawadhi S, Shah JJ, Valent J, Rosenzweig M, Lipe B, Zonder JA, Fredette S, Durie B, Hoering A, Bartlett B, Orlowski RZ.

Blood Cancer J. 2015 Aug 7;5:e334. doi: 10.1038/bcj.2015.62. No abstract available.

11.

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, Haideri NA, Yacoub A, Hess G, Lentzsch S, Spicka I, Chanan-Khan AA, Raab MS, Tarantolo S, Vij R, Zonder JA, Huang X, Jayabalan D, Di Liberto M, Huang X, Jiang Y, Kim ST, Randolph S, Chen-Kiang S.

Leuk Lymphoma. 2015;56(12):3320-8. doi: 10.3109/10428194.2015.1030641. Epub 2015 May 15.

PMID:
25813205
12.

Photonic detection and characterization of DNA using sapphire microspheres.

Murib MS, Yeap WS, Martens D, Bienstman P, De Ceuninck W, van Grinsven B, Schöning MJ, Michiels L, Haenen K, Ameloot M, Serpengüzel A, Wagner P.

J Biomed Opt. 2014 Sep;19(9):97006. doi: 10.1117/1.JBO.19.9.097006.

PMID:
25260868
13.

Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma.

Abidi MH, Gul Z, Abrams J, Ayash L, Deol A, Ventimiglia M, Lum L, Mellon-Reppen S, Al-Kadhimi Z, Ratanatharathorn V, Zonder J, Uberti J.

J Chemother. 2012 Jun;24(3):167-72. doi: 10.1179/1973947812Y.0000000004.

14.

Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.

Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M, Martin T, Schlossman R, Ghobrial IM, Munshi N, Laubach J, Allerton J, Hideshima T, Colson K, Poradosu E, Gardner L, Sportelli P, Anderson KC.

J Clin Oncol. 2011 Nov 10;29(32):4243-9. doi: 10.1200/JCO.2010.33.9788. Epub 2011 Oct 11.

PMID:
21990396
15.

Dermatological complications following initiation of lenalidomide in a patient with chronic lymphocytic leukaemia.

Tageja N, Giorgadze T, Zonder J.

Intern Med J. 2011 Mar;41(3):286-8. doi: 10.1111/j.1445-5994.2011.02426.x.

PMID:
21426467
16.

Plasma cell leukemia presenting as organizing pneumonia refractory to high-dose steroid therapy.

Tageja N, Nagi J, Valent J, Zonder J.

South Med J. 2010 Jul;103(7):706-10. doi: 10.1097/SMJ.0b013e3181e206da.

PMID:
20531051
17.

Positive pregnancy tests in a postmenopausal woman due to beta-human chorionic gonadotropin production by multiple myeloma.

Tageja N, Valent J, Giorgadze T, Bentley G, Zonder J.

Am J Med Sci. 2010 Feb;339(2):182-4. doi: 10.1097/MAJ.0b013e3181bccedb.

PMID:
20145436
18.

Treatment of relapsed acute promyelocytic leukemia with gemtuzumab ozogamicin and all-trans retinoic acid.

Tageja N, Valent J, Zonder J.

J Chemother. 2009 Dec;21(6):705-6. No abstract available.

PMID:
20071299
19.

Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).

Hussein MA, Bolejack V, Zonder JA, Durie BG, Jakubowiak AJ, Crowley JJ, Barlogie B.

J Clin Oncol. 2009 Jul 20;27(21):3510-7. doi: 10.1200/JCO.2008.19.9240. Epub 2009 Jun 22.

20.

Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes.

Mohamed AN, Bentley G, Bonnett ML, Zonder J, Al-Katib A.

Am J Hematol. 2007 Dec;82(12):1080-7.

Supplemental Content

Loading ...
Support Center